Elicio Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: ELTX · Form: 10-K · Filed: Mar 29, 2024 · CIK: 1601485

Elicio Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyElicio Therapeutics, Inc. (ELTX)
Form Type10-K
Filed DateMar 29, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Elicio Therapeutics, Annual Report, Pharmaceuticals, SEC Filing

TL;DR

<b>Elicio Therapeutics, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

Elicio Therapeutics, Inc. (ELTX) filed a Annual Report (10-K) with the SEC on March 29, 2024. Elicio Therapeutics, Inc. (formerly Angion Biomedica Corp.) filed its 2023 Form 10-K on March 29, 2024. The company's fiscal year ends on December 31st. Elicio Therapeutics is incorporated in Delaware. The company's principal business address is 451 D Street, 5th Floor, Boston, MA 02210. The filing covers the fiscal year ended December 31, 2023.

Why It Matters

For investors and stakeholders tracking Elicio Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Elicio Therapeutics' financial health, operational status, and strategic direction for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects. The filing includes detailed financial statements, risk factors, and management's discussion and analysis, offering insights into the company's challenges and opportunities within the pharmaceutical preparations industry.

Risk Assessment

Risk Level: low — Elicio Therapeutics, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant financial or operational disclosures that would alter the company's risk profile beyond what is typically expected for a public company in this sector.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand Elicio Therapeutics' current financial position and potential challenges.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed period of report)
  • 2024-03-29 — Filing Date (Filed as of date)
  • 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

  • Elicio Therapeutics, Inc. (company) — Filer name
  • Angion Biomedica Corp. (company) — Former company name
  • Boston, MA (location) — Business address city and state
  • DE (location) — State of incorporation

FAQ

When did Elicio Therapeutics, Inc. file this 10-K?

Elicio Therapeutics, Inc. filed this Annual Report (10-K) with the SEC on March 29, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Elicio Therapeutics, Inc. (ELTX).

Where can I read the original 10-K filing from Elicio Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Elicio Therapeutics, Inc..

What are the key takeaways from Elicio Therapeutics, Inc.'s 10-K?

Elicio Therapeutics, Inc. filed this 10-K on March 29, 2024. Key takeaways: Elicio Therapeutics, Inc. (formerly Angion Biomedica Corp.) filed its 2023 Form 10-K on March 29, 2024.. The company's fiscal year ends on December 31st.. Elicio Therapeutics is incorporated in Delaware..

Is Elicio Therapeutics, Inc. a risky investment based on this filing?

Based on this 10-K, Elicio Therapeutics, Inc. presents a relatively low-risk profile. The filing is a standard annual report (10-K) and does not contain immediate, significant financial or operational disclosures that would alter the company's risk profile beyond what is typically expected for a public company in this sector.

What should investors do after reading Elicio Therapeutics, Inc.'s 10-K?

Review the detailed financial statements and risk factors within the 10-K to understand Elicio Therapeutics' current financial position and potential challenges. The overall sentiment from this filing is neutral.

How does Elicio Therapeutics, Inc. compare to its industry peers?

Elicio Therapeutics operates within the pharmaceutical preparations industry, focusing on the development and commercialization of novel therapeutics.

Are there regulatory concerns for Elicio Therapeutics, Inc.?

As a public company, Elicio Therapeutics is subject to the reporting requirements of the Securities Exchange Act of 1934, including the annual filing of a Form 10-K.

Industry Context

Elicio Therapeutics operates within the pharmaceutical preparations industry, focusing on the development and commercialization of novel therapeutics.

Regulatory Implications

As a public company, Elicio Therapeutics is subject to the reporting requirements of the Securities Exchange Act of 1934, including the annual filing of a Form 10-K.

What Investors Should Do

  1. Analyze the financial statements for revenue, expenses, and cash flow.
  2. Review the 'Risk Factors' section for potential business and financial challenges.
  3. Examine the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' for insights into business performance.

Key Dates

  • 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
  • 2024-03-29: Filing Date — Date the 10-K was officially filed with the SEC.

Year-Over-Year Comparison

This filing is the 2023 Form 10-K for Elicio Therapeutics, Inc., detailing its annual performance.

Filing Stats: 4,316 words · 17 min read · ~14 pages · Grade level 18.8 · Accepted 2024-03-29 13:58:52

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 ELTX The Nasdaq Global Select Market

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Annual Report on Form 10-K, including the sections titled "Business", "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations", contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Annual Report on Form 10-K other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 and any other future product candidates, our ability to continue as a going concern and our cash runway; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in cancer and infectious disease; the timing, progress and results of clinical trials for ELI-002, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will becom

Business

Item 1. Business Overview We are a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer and infectious disease. Our proprietary Amphiphile ("AMP") technology is designed to mobilize the body's immune response by preferentially targeting our product candidates to the lymph nodes with the goal of generating a robust T cell response. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit. We believe the therapeutic utility of currently approved and development stage immunotherapies are limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity. Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response. We have developed our cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens. This strategy results in an "off-the-shelf" therapeutic option allowing patients to receive treatment without delay due to manufacturing timelines and costs associated with personalized vaccine approaches. Our clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, currently being evaluated in a Phase 2 clinical program, designed to stimulate an immune response against mutant KRAS cancers, ELI-007, currently being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 ("BRAF") -driven cancers, and ELI-008, currently being evaluated in a preclinical study for use in the treatment of

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.